Research work · 2002
Imatinib Mesylate and Gray Hair
Gabriel Étienne, Pascale Cony‐Makhoul, François‐Xavier Mahon
New England Journal of Medicine
Abstract
To the Editor: The impressive effects of the tyrosine kinase inhibitor STI571 (imatinib mesylate) in chronic myeloid leukemia were confirmed in the large trial by Kantarjian et al. (Feb. 28 issue).1 We would like to report a new side effect of the drug. Between December 1999 and June 2001, we treated 133 patients with chronic myeloid leukemia with imatinib mesylate according to Novartis Pharma protocols.1,2 Among these 133 patients, 5 men and 4 women (median age, 63.4 years; range, 53 to 75) with gray hair before treatment had progressive repigmentation of the hair (on the head in 8 patients . . .